NIH Meeting: Open to Public, Closed to Secrets
Published Date: 3/17/2026
Notice
Summary
The National Institute of Environmental Health Sciences is holding a partly open meeting on June 15, 2026, where some sessions will be private to protect sensitive info. Scientists, staff, and the public (online) can join parts of the meeting to learn about research updates and ask questions. This meeting helps guide important health research but doesn’t involve new money or big changes.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Watch the NIEHS Meeting Online
You can watch the open parts of the Board of Scientific Counselors meeting on June 15, 2026 via the NIH Videocasting website (http://videocast.nih.gov/). The notice lists open session times on that date: 9:15–9:45 a.m., 9:45 a.m.–12:15 p.m., and 1:30–2:45 p.m.
Some Sessions Are Closed to the Public
Parts of the June 15, 2026 meeting are closed (for example 8:00–9:00 a.m.; 12:15–1:30 p.m.; 2:45–3:30 p.m.; 3:30–4:00 p.m.; and 4:00–5:00 p.m.) under 5 U.S.C. 552b(c)(4) and (c)(6) to protect confidential trade secrets, commercial property, and personal information. Those closed sessions will not be open for public viewing or participation.
How to Submit Oral or Written Comments
Any interested person may file written comments by forwarding a statement (including name, address, telephone number, and affiliation when applicable) to the contact person. To present oral comments at the meeting you must notify the Contact Person at least 10 days before the meeting; only one representative per organization may present and presentations may be limited to five minutes.
On‑Campus Security Requirements for Attendees
If you plan to attend on-campus, NIH requires visitors to follow security procedures (for example, show one form of identification such as a government-issued photo ID, driver's license, or passport) and all visitor vehicles will be inspected; details are at https://www.nih.gov/about-nih/visitor-information/campus-access-security. These requirements apply to visitors attending meetings on campus or at off‑campus federal facilities.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2026-05149, Foreign-Trade Zone (FTZ) 84, Notification of Proposed Production Activity; AuroraTe LLC; (Galvanized Steel Pipes); Houston, Texas
AuroraTe LLC in Houston wants to make galvanized steel pipes using special steel coils inside Foreign-Trade Zone 84. This means they can save on import taxes while making their products. People have until April 27, 2026, to share their thoughts before the plan moves forward.
Next: 2026-05151, Initiation of Section 301 Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure To Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced With Forced Labor
The U.S. is launching investigations into countries that aren’t stopping goods made with forced labor from entering the market. This means businesses and governments involved in importing these products could face new rules or penalties soon. Public comments and hearings are open now, with key deadlines in April 2026, signaling possible trade changes and financial impacts ahead.